Semaglutide: FDA records on compounded and unapproved products
Has FDA taken action on compounded semaglutide?
Yes. As of Nov 15, 2026, FDA has issued 148 warning letters to 144 companies whose text names semaglutide, the latest dated Oct 30, 2026, and openFDA lists 52 recall reports naming it. FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list (statement dated Apr 1, 2026).
As of Nov 15, 2026, FDA’s drug shortage data lists semaglutide only with status “To Be Discontinued” (Semaglutide Tablet).
What FDA has stated, by date
- Feb 21, 2025: FDA determined that the shortage of semaglutide injection products is resolved. FDA said it did not intend to take action, for violations that depend on semaglutide being on the shortage list, against 503A pharmacies and physicians until April 22, 2025, or 503B outsourcing facilities until May 22, 2025 (or a pending court decision, whichever was later). The same update listed liraglutide injection as in shortage. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 24, 2025: A federal district court denied the preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). FDA stated (update dated April 28, 2025) that the enforcement discretion period for 503A semaglutide compounding had ended, and that for 503B outsourcing facilities it ran until May 22, 2025. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Sep 5, 2025: FDA established a “green list” import alert (Import Alert 66-80) for GLP-1 active pharmaceutical ingredients. APIs from facilities on the list may enter; APIs from other sources are subject to detention without physical examination. Source: FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 1, 2026: FDA restated the section 503A conditions: compounding for an individual patient on a prescription, and not compounding regularly or in inordinate amounts drugs that are essentially copies of a commercially available drug. FDA gave semaglutide combined with vitamin B12 (cyanocobalamin) as an example that may be considered essentially a copy, and said that at this time it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- Apr 30, 2026: FDA announced a proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, stating it did not identify a clinical need for outsourcing facilities to compound them from bulk drug substances. FDA said it would consider public comments before a final determination. Source: FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- May 1, 2026: The proposal was published in the Federal Register (Docket No. FDA-2018-N-3240, 91 FR 23431) with comments due June 30, 2026. Source: Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Jun 26, 2026: FDA extended to July 30, 2026 the comment period on its proposal not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list. Source: Federal Register, June 26, 2026: Extension of Comment Period
- Oct 1, 2026: FDA states it has warned companies that sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption,” sold directly to consumers with dosing instructions. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- Oct 1, 2026: FDA states that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than those in the approved drugs, and that it is not aware of any lawful basis for their use in compounding. Source: FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA’s page does not date each paragraph; the date shown is the page’s “content current as of” date.
FDA drug shortage status
| Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) | Novo Nordisk, Inc. | To Be Discontinued | Jun 4, 2026 |
| Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) | Novo Nordisk, Inc. | To Be Discontinued | Jun 4, 2026 |
| Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) | Novo Nordisk, Inc. | To Be Discontinued | Jun 4, 2026 |
Shortage history, by date
| FDA’s words or record | Source | ||
|---|---|---|---|
| Mar 31, 2022 | Listed | “Wegovy was approved by FDA in June 2021 (NDA 215256) and added to FDA’s drug shortage list on March 31, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Aug 23, 2022 | Listed | “Ozempic was approved by FDA in December 2017 (NDA 209637) and added to FDA’s drug shortage list on August 23, 2022.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Feb 21, 2025 | Resolved | “FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Apr 22, 2025 | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until April 22, 2025” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 24, 2025 | Litigation | “On April 24, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) regarding compounded semaglutide.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| May 22, 2025 | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until May 22, 2025.” | FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) |
| Apr 1, 2026 | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Jun 4, 2026 | To Be Discontinued | FDA’s shortage data posts Semaglutide Tablet (Rybelsus) with status “To Be Discontinued,” first posted Jun 4, 2026: 3 presentations. | FDA drug shortage data, via openFDA drug shortages endpoint |
All GLP-1 drugs on one timeline: shortage history.
FDA adverse event reports (FAERS) listing semaglutide
openFDA’s copy of FDA’s adverse event database holds 111,278 reports that list semaglutide, received from Jan 23, 2013 through Sep 30, 2026. 56,072 (50%) are marked serious by the reporter, including 1,741 that list death as an outcome. 217 reports name a compounded or combination semaglutide product in the product fields. These are unverified reports and do not show that the drug caused any event.
FAERS reports are sent to FDA by drug makers, health professionals and the public. FDA does not verify them, a report does not show that the drug caused the event, and the same event can be reported more than once. Counts reflect how often events were reported, not how often they happen or how risky a drug is. Nothing here is medical advice. Report an error or add a company response.
Reports by year FDA received them
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 8 |
| 2016 | 20 |
| 2017 | 21 |
| 2018 | 1,168 |
| 2019 | 1,833 |
| 2020 | 3,960 |
| 2021 | 5,521 |
| 2022 | 8,078 |
| 2023 | 11,886 |
| 2024 | 19,166 |
| 2025 | 27,521 |
| 2026 | 32,090 |
Reaction terms listed most often
| Nausea | 15,624 | 14.0% |
| Vomiting | 10,416 | 9.4% |
| Off label use | 9,566 | 8.6% |
| Diarrhoea | 8,804 | 7.9% |
| Constipation | 6,481 | 5.8% |
| Decreased appetite | 6,105 | 5.5% |
| Weight decreased | 5,518 | 5.0% |
| Fatigue | 4,798 | 4.3% |
| Impaired gastric emptying | 4,549 | 4.1% |
| Headache | 4,479 | 4.0% |
A report can list several reaction terms. Terms such as “Off label use” or “Incorrect dose administered” describe how the drug was used, not a bodily reaction.
Reports naming a compounded or combination semaglutide product
In openFDA’s public copy of FDA’s adverse event data, checked Nov 15, 2026, 217 reports of the 111,278 listing semaglutide have product text that identifies a compounded or combination product: 210 list semaglutide combined with a vitamin or amino acid such as cyanocobalamin (vitamin B12), and 8 use the word “compounded” or “compound” in the product name or dosage text (1 meets both tests). The public data has no compounded flag and no narrative, so this is a floor, not a full count, and the reports are unverified. More on the compounded semaglutide reports page.
A report is counted as naming a compounded product only when one drug entry in it names the drug and that same entry either uses the word “compounded”, “compounding” or “compound” in its product name or dosage text, or lists the drug together with cyanocobalamin, methylcobalamin, pyridoxine, glycine, levocarnitine, carnitine, niacinamide or vitamin B12 or B6 in one product name, a combination no FDA-approved product of these drugs contains. openFDA’s public data has no field that marks a product as compounded and leaves out the report narrative, so this finds only reports whose product text shows it. FDA’s own counts for compounded semaglutide and tirzepatide, from its full internal data, are higher.
| Report | |||||
|---|---|---|---|---|---|
| Sep 30, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27332952 |
| Sep 28, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27319074 |
| Sep 26, 2026 | LEVOCARNITINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27317300 |
| Sep 24, 2026 | PYRIDOXINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27310872 |
| Sep 24, 2026 | METHYLCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27311146 |
| Sep 17, 2026 | LEVOCARNITINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27278064 |
| Sep 16, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27272422 |
| Sep 16, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27272458 |
| Sep 15, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27262024 |
| Sep 11, 2026 | GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27248253 |
| Sep 11, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27248523 |
| Aug 31, 2026 | PYRIDOXINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27195587 |
| Aug 31, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27196661 |
| Aug 28, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27181342 |
| Aug 28, 2026 | PYRIDOXINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27184633 |
| Aug 28, 2026 | SEMAGLUTIDE | Product text says compounded | Suspect | No | openFDA 27184699 |
| Aug 28, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27184825 |
| Aug 28, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27184878 |
| Aug 28, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27189965 |
| Aug 27, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27183056 |
| Aug 27, 2026 | CYANOCOBALAMIN\GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27183058 |
| Aug 26, 2026 | GLYCINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27178113 |
| Aug 24, 2026 | CYANOCOBALAMIN\NADIDE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | Yes | openFDA 27161750 |
| Aug 24, 2026 | PYRIDOXINE\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27161754 |
| Aug 24, 2026 | CYANOCOBALAMIN\SEMAGLUTIDE | Combined with a vitamin or amino acid | Suspect | No | openFDA 27166227 |
The 25 most recent are shown; all 217 are on the adverse event reports page.
Active ingredient (API) imports: FDA import alert and refusal records
FDA’s Import Alert 66-80 Green List (published Oct 9, 2026) has 10 entries naming semaglutide, in China (7), Belgium (1), Denmark (1) and Portugal (1); FDA redacts the firm names. FDA’s import refusal records list 501 refused shipment lines whose product code names semaglutide, from Jun 16, 2023 to Oct 30, 2026, most often from Canada (208), Denmark (149) and United States (26); 11 carry an API or powder product code listed on the alert.
Import Alert 66-80 Green List entries naming semaglutide
| Product codes and drugs listed | |||
|---|---|---|---|
| 1 | Redacted by FDA | BELGIUM | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]75 Exenatide (Anti-Diabetic) |
| 4 | Redacted by FDA | CHINA | 56F[][]99 Peptide N.E.C. (Antibiotics) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]99 Anti-Diabetic N.E.C. (Anti-Diabetic) |
| 5 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 7 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 8 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 10 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 12 | Redacted by FDA | CHINA | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 13 | Redacted by FDA | CHINA | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]74 Tirzepatide (Anti-Diabetic) |
| 15 | Redacted by FDA | DENMARK | 61P[][]76 Liraglutide (Anti-Diabetic) 61P[][]72 Semaglutide (Anti-Diabetic) |
| 20 | Redacted by FDA | PORTUGAL | 61P[][]72 Semaglutide (Anti-Diabetic) 61P[][]77 Orforglipron SDD (Anti-Diabetic) |
Refused semaglutide lines by country and form
| Canada | 208 |
| Denmark | 149 |
| United States | 26 |
| China | 19 |
| Colombia | 17 |
| United Kingdom | 15 |
| India | 14 |
| Mexico | 11 |
| Brazil | 9 |
| Bangladesh | 5 |
| Germany | 4 |
| Singapore | 4 |
| France | 3 |
| Hong Kong | 2 |
| Israel | 2 |
| Japan | 2 |
| Nigeria | 2 |
| Albania | 1 |
| Bulgaria | 1 |
| Egypt | 1 |
| Greece | 1 |
| Honduras | 1 |
| Indonesia | 1 |
| Italy | 1 |
| Philippines | 1 |
| Turkey | 1 |
| Code not listed on Import Alert 66-80 | 490 |
| Active Pharm Ingred/Chems for Rx Compounding | 8 |
| NonSterile Powder | 2 |
| Active Pharm Ingred/Chems for Further Manuf | 1 |
Most recent refused semaglutide lines
| Shipment ID | |||||
|---|---|---|---|---|---|
| Oct 30, 2026 | NOVO NORDISK | Canada | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-8781355-7/10003/1 |
| Oct 14, 2026 | Name not shown | France | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | SCS-5123290-6/10003/1 |
| Oct 7, 2026 | XU LIHUA JINGFANG Trading Co. LTD | China | 61PIR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | XXX-0763336-3/1/4 |
| Sep 18, 2026 | Name not shown | United States | 61PDY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9731409-8/20001/1 |
| Sep 9, 2026 | Name not shown | France | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | SCS-5013553-0/10003/1 |
| Aug 31, 2026 | NOVO NORDISK | Canada | 61PCL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 799-1109746-0/10003/1 |
| Aug 18, 2026 | Novo Nordisk A/S | Denmark | 61PCP72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 9H5-0019713-6/10002/1 |
| Aug 14, 2026 | Novo Nordisk A/S | Denmark | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0899165-4/10002/1 |
| Aug 13, 2026 | Novo Nordisk A/S | Denmark | 61PCK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-2262166-8/10002/1 |
| Aug 12, 2026 | Novo Nordisk A/S | Denmark | 61PCP72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 9H5-0019708-6/10002/1 |
| Jul 30, 2026 | Novo Nordisk A/S | Denmark | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-3429534-5/10002/1 |
| Jul 24, 2026 | Novo Nordisk A/S | Denmark | 61PCL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-3078600-8/10002/1 |
| Jul 21, 2026 | Novo Nordisk A/S | Denmark | 61PCE72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0505963-8/10002/1 |
| Jul 13, 2026 | ASIAN SUITS ONLINE LIMITED | United Kingdom | 61PIK72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | ITC-0045415-9/10002/1 |
| Jul 10, 2026 | NOVO NORDISK | Canada | 61PDY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0725103-5/10002/1 |
| Jun 30, 2026 | Hybio Pharmaceutical Co., Ltd. | China | 61PBY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 8NP-0146038-9/10002/1 |
| Jun 29, 2026 | NOVO NORDISK INDIA PRIVATE LIMIT | India | 61PCY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-9338523-3/30003/1 |
| Jun 26, 2026 | Name not shown | India | 61PBY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | AEK-0581038-6/10002/1 |
| Jun 22, 2026 | Novo Nordisk Inc. | United States | 61PCL72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-5519360-0/10001/1 |
| Jun 12, 2026 | Pharmhub Pharmacy | United Kingdom | 61PDY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 1FX-0303880-9/10002/1 |
The 20 most recent of 501 are shown, with charges, on the GLP-1 import records page and in the CSV download.
All firms and countries: Firms on GLP-1 import records. Answer page: Where does compounded semaglutide API come from?
FDA NDC Directory listings
FDA’s NDC Directory files read Nov 15, 2026 carry 188 listings naming semaglutide: BULK INGREDIENT (56); OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (38); BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING (35); NDA (32); DRUG FOR FURTHER PROCESSING (27). Outsourcing facility listings: Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA? Every listing: GLP-1 listings in FDA’s NDC Directory. FDA says an NDC “does not in any way denote FDA approval of the product.”
Medicare and Medicaid spending on semaglutide
Medicare Part D spent $15.16 billion on semaglutide brands in 2024 (Ozempic $12.97 billion, Rybelsus $1.89 billion, Wegovy $301.3 million), before manufacturer rebates, according to CMS. Pharmacies were reimbursed at least $6.61 billion for semaglutide products paid through Medicaid nationwide in 2025, across at least 5,892,727 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 21 rows of 132, so these figures are floors.
Medicare Part D, by brand and year
| Ozempic | Semaglutide | $1,455,812,267 | $2,621,694,348 | $4,628,160,643 | $9,194,048,435 | $12,970,296,347 |
| Rybelsus | Semaglutide | $73,444,409 | $454,563,823 | $974,894,470 | $1,665,906,943 | $1,890,082,026 |
| Wegovy | Semaglutide | No data | No data | No data | $199,774 | $301,283,291 |
Medicaid, nationwide, by year
| 2020 | at least $283,898,491 |
| 2021 | at least $554,820,690 |
| 2022 | at least $1,149,248,802 |
| 2023 | at least $2,911,348,586 |
| 2024 | at least $5,107,538,873 |
| 2025 | at least $6,613,338,249 |
| 2026 (Q1) | at least $1,251,443,577 |
Figures are before manufacturer rebates, as CMS reports them. Every GLP-1 drug, CMS’s caveats and each state: Medicare and Medicaid spending on GLP-1 drugs.
FDA warning letters naming semaglutide
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Oct 30, 2026 | RonanRx, Inc. dba RonanRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 24, 2026 | Cheap Medicine Shop/www.cheapmedicineshop.com | Unapproved New Drugs/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 23, 2026 | Online Generic Medicine/www.onlinegenericmedicine.com | Unapproved New Drug/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 18, 2026 | Empower Clinic Services, LLC dba Empower Pharmacy | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | TXP Innovations LLC dba Tex Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Royal Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | NuScience Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peptide Partners LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peak Performance Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Maximus Health, Inc. dba Maximus | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Trinity HealthCare Supply, LLC dba altRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Glow Medispa, LLC dba Mint Med | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Ezra Holdco LLC dba Ezra | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Public Health Solution LLC dba DrMedHealth | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | D&H Medical Services | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Amie Health, Inc. dba Amie | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Altru Telehealth, LLC dba Altru Telehealth | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Eden Health International Inc. dba Eden | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | NativeMed LLC dba NativeMed | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | FitRX, LLC dba AM RX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Momentum Health 360 dba Momentum Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Medica Weight Loss | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Clover Meds LLC dba Clover Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nexlife Inc. dba Nexlife | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Roen Health, Inc. dba RoenRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Joi and Blokes dba Joi + Blokes | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | VivioMD Group LLC dba VivioMD | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Thrivelab Co. dba Thrivelab | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nexus Health Solutions LLC dba Harper Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Nova Vascular LLC dba NOVARX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Ready Med | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | OrderlyMeds LLC dba OrderlyMeds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | HydraMed IV LLC dba HydraMed | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | FITISH | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| May 1, 2026 | Harbin Jixianglong Biotech Co., Ltd. | CGMP/API/Adulterated and Misbranded Drugs | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 14, 2026 | New Life Pharma LLC | CGMP/Adulterated and Unapproved New Drug/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 7, 2026 | ProRx LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Prime Sciences | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Mar 31, 2026 | Mile High Compounds LLC | Unapproved New Drugs Sold Over the Internet | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Premium Health Management Inc. dba Premium Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Bliv Wellness LLC dba Bliv | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | BluefitMD | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Aspen Aesthetics dba Fifty 410 | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | FitRX, LLC dba FitRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Genesis Health International Inc. dba Genesis | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Lean Rx, Inc. dba SkinnyRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Kare Solutions, LLC dba Zappy | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Strut Health, LLC dba Strut | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Refills Health, LLC dba Refills Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Weightless Medical LLC dba WeightCare | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Viv Health, Inc. dba VIV RX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Peaks Curative, LLC dba Peaks | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | PharmaZee | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Good Girl LLC dba GoodGirlRX | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Ivim Services LLC dba Ivim | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Join Josie | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Kin Meds | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Levity Inc. dba Levity | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Liraglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | MaxLife Technologies Inc. dba Maxlife | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Better Health Labs, Inc. dba Measured | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | MEDVi, LLC dba MEDVi | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Newman Clinic, PLLC dba Newman Clinic | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | NewSelf Limited dba NewSelf | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | 24HrDoc, Inc. dba 24HrDoc | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Alan Health Technologies Inc. dba Alan | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Dripgym Mobile Parent, LLC dba Amp Health | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 20, 2026 | Belle Health LLC dba Belle | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 20, 2026 | GenoGenix LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 16, 2026 | Boothwyn Pharmacy, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 1, 2025 | Apothecary Pharma, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Oct 10, 2025 | PQ Pharmacy, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 11, 2025 | Chengdu Brilliant Biopharmaceutical Co., Ltd. | CGMP/Finished Pharmaceuticals/Adulterated | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 10, 2025 | motionpharmacy.com | Unapproved New Drug/Misbranded | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Expert Aesthetics | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Healthy Living Clinic | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Hims & Hers Health, Inc. dba Hers | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Amazing Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GenLabMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | FitRX, LLC dba Zealthy | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Get.Fit.Medical, LLC dba Get.Fit.Medical | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | FWD Care, Inc. dba FWD | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | iVisitDoc, Inc. dba iVisitDoc | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lean Dreams LLC dba LeanDreams | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ybycmeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Try Nova | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | The HCG Institute | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Vitals RX | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Las Villas Health Care LLC dba Villas Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Tuyo Health, Inc. dba Tuyo Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lovely Meds, Inc. dba Lovely Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lyfe Rx | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | inspire.clinic | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Bioverse, Inc. dba Bioverse | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | SimpleRx | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Elevate Your Wellness LLC, dba Elevated | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Cosmo Medical Spa dba Cosmo Med Spa | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EvoLife Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Nuvo Life Health Inc. dba Nuvo Life Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | SemaBio | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | directmeds.com, Inc. dba DirectMeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Hims & Hers Health, Inc. dba Hims | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | MedClub by Dr. Jenn | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Mane & Steel, LLC. dba Mane & Steel | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Lumimeds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | GLP-1 Solution | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | ASN-LABS | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Body Good Studio | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Canada Med Stop | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | All American Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Intimate Rose | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Invigorate Med Spa | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Dr. Gater’s Weight Loss & Wellness | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Remedy Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | EA WORKS Limited Liability Company dba Trust Labs | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Fancy Meds, LLC dba Fancy Meds | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Matthew Stern, CEO MyStart Health LLC. | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Elite Health Center | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Curex | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Healthon Inc. dba Healthon | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | JulyMD | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Slendid | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Sprout Health Partners LLC dba Sprout Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Master Pharmaceuticals Group | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | TRYM Health, Inc. dba TRYM Health | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | HealBerry | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Reset IV, LLC dba Reset IV | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 9, 2025 | Healthy Male | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jul 29, 2025 | cheaptrustedpharmacy.com | Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 12, 2025 | www.buynetmeds.com | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| May 5, 2025 | www.peacefulmeds.com | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 23, 2025 | www.24hreup.biz | Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 8, 2025 | Tailstorm Health Inc. dba Medivant Health | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | Close-out letter, Apr 14, 2026 | fda.gov |
| Mar 4, 2025 | ProRx, LLC | Compounding Pharmacy/Adulterated Drug Products | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 26, 2025 | USApeptide.com | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jan 13, 2025 | www.weightcrunchshop.com | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Prime Vitality, Inc. dba Prime Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Swisschems | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Xcel Research LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Cagrilintide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Dec 10, 2024 | Summit Research Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 12, 2024 | Nomida.biz | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 20, 2024 | AnuMed International, LLC | Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 24, 2024 | Ozempen.com | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Apr 24, 2024 | www.dashpct.com | Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | US Chem Labs | CGMP/Finished Pharmaceuticals/Adulterated | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Feb 7, 2024 | Synthetix Inc. DBA Helix Chemical Supply | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Oct 2, 2023 | www.semaspace.com | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Oct 2, 2023 | www.gorillahealing.com | Finished Pharmaceuticals/Unapproved New Drug/Misbranded | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Recalls naming semaglutide
| Record | ||||||
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 9/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0026-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE/CYANOCOBALAMIN 3/2 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescriptio... | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0019-2027 |
| Sep 10, 2026 | Carolina Infusion, LLC | SEMAGLUTIDE 3 MG/ML INJECTABLE, 8 x 0.1 mL syringes, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936 | Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. | Class II | Ongoing | D-0018-2027 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, S... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0755-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0747-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0748-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, S... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0753-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0749-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0752-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0757-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0756-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0751-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0750-2026 |
| Jul 29, 2026 | Apollo Care, LLC | SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 10... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0754-2026 |
| Mar 6, 2026 | PAYLESS COMPOUNDERS, LLC | Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR | Lack of Assurance of Sterility | Class II | Ongoing | D-0471-2026 |
| Feb 26, 2026 | New Life Pharma LLC | Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-06 | Lack of Assurance of Sterility | Class II | Ongoing | D-0393-2026 |
| Feb 26, 2026 | New Life Pharma LLC | Semaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, KS 66061, NDC 84223-001-07. | Lack of Assurance of Sterility | Class II | Ongoing | D-0392-2026 |
| Feb 13, 2026 | Harbin Jixianglong Biotech Co., Ltd. | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; ... | CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be... | Class II | Ongoing | D-0380-2026 |
| Feb 13, 2026 | Harbin Jixianglong Biotech Co., Ltd. | Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d... | CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation be... | Class II | Ongoing | D-0379-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 841... | Lack of Assurance of Sterility | Class II | Ongoing | D-0115-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84... | Lack of Assurance of Sterility | Class II | Ongoing | D-0116-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413... | Lack of Assurance of Sterility | Class II | Ongoing | D-0118-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84... | Lack of Assurance of Sterility | Class II | Ongoing | D-0117-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139... | Lack of Assurance of Sterility | Class II | Ongoing | D-0114-2026 |
| Oct 15, 2025 | ProRx LLC | Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 8413... | Lack of Assurance of Sterility | Class II | Ongoing | D-0119-2026 |
| Jul 30, 2025 | GenoGenix LLC | Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as m... | Lack of Assurance of Sterility | Class II | Ongoing | D-0091-2026 |
| Jul 30, 2025 | GenoGenix LLC | Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. | Lack of Assurance of Sterility | Class II | Ongoing | D-0083-2026 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, D... | Lack of Processing Controls. | Class II | Ongoing | D-0563-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dos... | Lack of Processing Controls. | Class II | Ongoing | D-0564-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate,... | Lack of Processing Controls. | Class II | Ongoing | D-0562-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do n... | Lack of Processing Controls. | Class II | Ongoing | D-0553-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate... | Lack of Processing Controls. | Class II | Ongoing | D-0561-2025 |
| Jul 18, 2025 | AEQUITA PHARMACY | Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate,... | Lack of Processing Controls. | Class II | Ongoing | D-0565-2025 |
| Jul 9, 2025 | Boothwyn Pharmacy LLC | Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0608-2025 |
| Jul 9, 2025 | Boothwyn Pharmacy LLC | Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0606-2025 |
| Jul 9, 2025 | Boothwyn Pharmacy LLC | Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy | Subpotent Drug | Class II | Ongoing | D-0609-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0480-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0479-2025 |
| May 21, 2025 | Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) | Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | Lack of Assurance of Sterility | Class II | Ongoing | D-0481-2025 |
| Aug 22, 2024 | ProRx LLC | Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0650-2024 |
| Aug 22, 2024 | ProRx LLC | Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02 | Lack of Assurance of Sterility | Class II | Ongoing | D-0654-2024 |
| Aug 22, 2024 | ProRx LLC | SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01 | Lack of Assurance of Sterility | Class II | Ongoing | D-0652-2024 |
| Aug 22, 2024 | ProRx LLC | SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04 | Lack of Assurance of Sterility | Class II | Ongoing | D-0653-2024 |
| Aug 15, 2023 | TMC Acquisitions LLC dba Tailor Made Compounding | Semaglutide/Cyanocobalamin 2mg/0.4mg/mL, 1mLvials, Tailor Made Compounding. | Lack of Assurance of Sterility | Class II | Terminated | D-1105-2023 |
| Apr 13, 2023 | Pharmacy Plus, Inc. dba Vital Care Compounder | C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402 | Lack of assurance of sterility. | Class II | Ongoing | D-0538-2023 |
| Dec 22, 2022 | Pharmacy Innovations | SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML ... | Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility. | Class II | Terminated | D-0236-2023 |
| Oct 7, 2022 | Pharmacy Plus, Inc. dba Vital Care Compounder | SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402 | Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility ... | Class II | Ongoing | D-0053-2023 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1521-2022 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 5/2 MG/ML Injectable, 0.2 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1519-2022 |
| Aug 26, 2022 | Carolina Infusion | Semaglutide/Cyanocobalamin 10/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | Lack of Assurance of Sterility | Class II | Completed | D-1520-2022 |
| Mar 7, 2022 | TMC Acquisition LLC dba Tailor Made Compounding | Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate, Tailor Made Compounding | Lack of Assurance of Sterility | Class II | Ongoing | D-1225-2022 |
| Mar 7, 2022 | TMC Acquisition LLC dba Tailor Made Compounding | Semaglutide/Cyanocobalamin 2mg/0.4mg/ml, 1mL-vial, Refrigerate, Tailor Made Compounding | Lack of Assurance of Sterility | Class II | Ongoing | D-1224-2022 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letters (fda.gov full-text search)
- openFDA drug recall enforcement reports
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA Adverse Event Reporting System (FAERS), via openFDA drug event endpoint
- FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA news release: FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
- FDA news release: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Federal Register, May 1, 2026: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B
- Federal Register, June 26, 2026: Extension of Comment Period
- FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- CMS Medicare Part D Spending by Drug (data.cms.gov)
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.